PROTAC Degrader Deal Benchmarks in Oncology

Median Upfront

$348M

Range: $194M - $492M

Total Deal Value

$2.2B

Range: $1.4B - $3.0B

Royalty Rate

12.9% - 21.1%

Tiered up to 25.1%

Dev Milestones

$466M

Range: $311M - $623M

Model Your Deal

Market Analysis

PROTAC Degrader therapies in oncology have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 protac degrader asset in oncology is $348M, with total deal values reaching $2.2B. Development milestones average $466M, while regulatory milestones contribute $745M.

The oncology protac degrader landscape is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for protac degrader oncology deals range from 12.9% to 21.1% at the base tier, with tiered escalation reaching 16.9%-25.1% on blockbuster sales. Commercial milestones averaging $652M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a protac degrader oncology licensing deal?

Based on our analysis, Phase 2 protac degrader licensing deals in oncology average $348M in upfront payments, with a range of $194M to $492M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for protac degrader oncology transactions?

The median total deal value for Phase 2 protac degrader assets in oncology is $2.2B, ranging from $1.4B to $3.0B. This includes development milestones ($466M), regulatory milestones ($745M), and commercial milestones ($652M).

What royalty rates are standard for protac degrader deals in oncology?

Base royalty rates for protac degrader oncology transactions range from 12.9% to 21.1%, with tiered escalations reaching 16.9%-25.1% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in protac degrader oncology deals?

PROTAC Degrader oncology deals allocate approximately 84% of total deal value to milestones. Development milestones ($466M) make up the largest share, followed by commercial milestones ($652M) and regulatory milestones ($745M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

Small Molecule in Oncology

View

Monoclonal Antibody in Oncology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating